• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

作者信息

Lugo T G, Pendergast A M, Muller A J, Witte O N

机构信息

Department of Microbiology, University of California, Los Angeles 90024.

出版信息

Science. 1990 Mar 2;247(4946):1079-82. doi: 10.1126/science.2408149.

DOI:10.1126/science.2408149
PMID:2408149
Abstract

Oncogenic activation of the proto-oncogene c-abl in human leukemias occurs as a result of the addition of exons from the gene bcr and truncation of the first abl exon. Analysis of tyrosine kinase activity and quantitative measurement of transformation potency in a single-step assay indicate that variation in bcr exon contribution results in a functional difference between p210bcr-abl and p185bcr-abl proteins. Thus, foreign upstream sequences are important in the deregulation of the kinase activity of the abl product, and the extent of deregulation correlates with the pathological effects of the bcr-abl proteins.

摘要

相似文献

1
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
Science. 1990 Mar 2;247(4946):1079-82. doi: 10.1126/science.2408149.
2
BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.BCR基因的首个外显子序列可特异性激活费城染色体阳性人类白血病中的BCR/ABL酪氨酸激酶致癌基因。
Mol Cell Biol. 1991 Apr;11(4):1785-92. doi: 10.1128/mcb.11.4.1785-1792.1991.
3
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.原癌基因产物p120CBL以及衔接蛋白CRKL和c-CRK将c-ABL、p190BCR/ABL和p210BCR/ABL与磷脂酰肌醇-3'激酶途径相连。
Oncogene. 1996 Feb 15;12(4):839-46.
4
Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.Bcr与Abl的相互作用:通过隔离Bcr实现c-Abl的致癌激活。
Cancer Res. 2003 Jan 15;63(2):298-303.
5
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.BCR-ABL诱导的肿瘤发生是通过与GRB-2衔接蛋白的SH2结构域直接相互作用介导的。
Cell. 1993 Oct 8;75(1):175-85.
6
Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.BCR 基因第一个外显子内的序列可抑制 c-Abl 的活化酪氨酸激酶以及 Bcr-Abl 癌蛋白。
Cancer Res. 1996 Nov 15;56(22):5120-4.
7
The function of BCR/ABL and related proto-oncogenes.BCR/ABL及相关原癌基因的功能。
Curr Opin Hematol. 1997 Jan;4(1):3-11. doi: 10.1097/00062752-199704010-00002.
8
BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.BCR-ABL酪氨酸激酶在第一个BCR外显子内主要在酪氨酸位点上发生自身磷酸化或使P160 BCR发生转磷酸化。
Oncogene. 1993 Jan;8(1):101-9.
9
BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.BCR-ABL致癌基因转化所必需的BCR序列以非磷酸酪氨酸依赖的方式与ABL SH2调节域结合。
Cell. 1991 Jul 12;66(1):161-71. doi: 10.1016/0092-8674(91)90148-r.
10
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.Bcr、Abl和Bcr-Abl蛋白在正常细胞和白血病细胞中的亚细胞定位以及表达与髓系分化的相关性。
J Clin Invest. 1993 Oct;92(4):1925-39. doi: 10.1172/JCI116786.

引用本文的文献

1
Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies.酪氨酸磷酸化蛋白质组分析鉴定出限制酪氨酸激酶抑制剂疗法疗效的细胞内在信号。
bioRxiv. 2025 Aug 27:2025.08.22.670548. doi: 10.1101/2025.08.22.670548.
2
Neddylation status determines the therapeutic sensitivity of tyrosine kinase inhibitors in chronic myeloid leukemia.Neddylation状态决定了慢性粒细胞白血病中酪氨酸激酶抑制剂的治疗敏感性。
Sci Rep. 2025 May 30;15(1):18978. doi: 10.1038/s41598-025-04153-7.
3
Real-world comparison of flumatinib and nilotinib as first-line therapy for patients with chronic phase chronic myeloid leukemia: a multicenter retrospective study.
氟马替尼与尼罗替尼作为慢性期慢性髓性白血病患者一线治疗的真实世界比较:一项多中心回顾性研究。
Ther Adv Med Oncol. 2025 Apr 29;17:17588359251335905. doi: 10.1177/17588359251335905. eCollection 2025.
4
Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy.多靶点、非门控嵌合抗原受体T细胞作为一种保护正常谱系用于血癌治疗的策略。
Front Immunol. 2025 Mar 21;16:1493329. doi: 10.3389/fimmu.2025.1493329. eCollection 2025.
5
Chronic myelogenous leukemia coexpressing V-e16a2, V-e13a2, e13a2, and e14a2 fusion transcripts: a case report and review of the literature.共表达V-e16a2、V-e13a2、e13a2和e14a2融合转录本的慢性粒细胞白血病:一例报告并文献复习
Front Oncol. 2024 Dec 12;14:1518387. doi: 10.3389/fonc.2024.1518387. eCollection 2024.
6
Fusion Genes in Myeloid Malignancies.髓系恶性肿瘤中的融合基因
Cancers (Basel). 2024 Dec 3;16(23):4055. doi: 10.3390/cancers16234055.
7
Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development.波纳替尼:其研发背后的药物化学史综述
Pharmaceuticals (Basel). 2024 Oct 11;17(10):1361. doi: 10.3390/ph17101361.
8
BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph leukemias?BCR::ABL1 蛋白水解靶向嵌合体 (PROTACs):Ph 白血病治疗的新前沿?
Leukemia. 2024 Sep;38(9):1885-1893. doi: 10.1038/s41375-024-02365-w. Epub 2024 Aug 4.
9
REXO5 promotes genomic integrity through regulating R-loop using its exonuclease activity.REXO5 通过其外切核酸酶活性调节 R 环来促进基因组完整性。
Leukemia. 2024 Oct;38(10):2150-2161. doi: 10.1038/s41375-024-02362-z. Epub 2024 Jul 30.
10
Vitamin C Supplementation in the Treatment of Autoimmune and Onco-Hematological Diseases: From Prophylaxis to Adjuvant Therapy.维生素 C 补充治疗自身免疫性和血液肿瘤疾病:从预防到辅助治疗。
Int J Mol Sci. 2024 Jul 2;25(13):7284. doi: 10.3390/ijms25137284.